A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Ku, Hsun Teresa, Ph.D. Research Bookmark and Share

Hsun Teresa Ku, Ph.D. Research

Identification and Characterization of Pancreatic Stem Cells
A functional pancreas consists of two types of tissue: exocrine and endocrine. The exocrine tissue mainly consists of acinar cells, which secrete bicarbonate and digestive enzymes. These secretions are collected by the pancreatic ductal system, which begins with centroacinar cells that are directly in contact with acinar cells. The prolongation of the terminal ducts, or alveoli, are lined by centroacinar cells and gradually merge into a main duct that drains into the duodenum. The endocrine tissue is organized as islets and contains cells that secrete glucagon, insulin, somatostatin, pancreatic polypeptide or grehlin. These endocrine hormones are released directly into the blood stream in response to metabolic signals.
 
Recently, there has been an intense interest in identifying pancreatic stem or progenitor cells, especially the endocrine progenitor cells, for the purpose of replacement therapy of Type 1 diabetes (T1D), a disease in which the insulin-secreting beta cells are specifically destroyed by autoimmunity. However, the existence of self-renewing multipotential stem cells in the pancreas remains elusive. Our laboratory is interested in the identification and characterization of pancreatic stem/progenitor cells, using both mouse models and cadaverous human pancreatic tissues for studies. We have established a quantitative and clonogenic progenitor cell assay in our laboratory, which will be a powerful tool to study the cellular and molecular mechanisms that govern the differentiation and proliferation of the pancreatic stem/progenitor cells at the single cell level.
 
Embryonic Stem Cell Therapy for Type 1 Diabetes
T1D is marked by a deficiency of the insulin-secreting β cells residing in the Islets of Langerhans within the pancreas due to autoimmune destruction. One of the long-term goals of our laboratory is to advance clinical cell-replacement therapy for patients with sever forms of T1D by developing a safe, reliable and abundant source of cells, derived from human stem cells that function like pancreatic islets. Toward this end, we have established an efficient and potentially cost-effective differentiation protocol, originally adapted from a mouse embryonic stem cell (ESC) differentiation method previously established in our laboratory, and generated a population of glucose-responsive, insulin-producing and secreting cells derived from human ESCs while in vitro. This cell population will be a suitable development candidate for clinical cell replacement therapy for T1D at City of Hope in the future.
 
Embryonic Stem Cells as a Cellular Tool for Screening of Molecules for Treatment of Diabetes
In the small molecule drug discovery field, the “bottom-up” approach, which is based on structural considerations of known targets, has not been as fruitful as was once promised. ESC technology ffers a potential solution to this bottleneck. ESCs can be grown in large numbers and maintained in a pluripotent state in vitro. They can also be induced in culture to differentiate into cells from all three germ layers in a relatively normal fashion that is faithful to development in vivo. Three properties make ES cells an ideal platform for drug discovery: first, ES cells can provide virtually inexhaustible quantities of target cells, which is necessary for screening of large numbers of compounds; second, ES cells can differentiate into mature cells with phenotypes that mimic their counterparts in vivo; and third, compared with immortalized cell lines, ES cells and their derivatives will provide a much more accurate platform for the “top-down” drug screening approach. Our laboratory is interested in high throughput screening (HTS) of small molecules that may affect proliferation, differentiation and/or maturation of the pancreatic insulin-producing  β cells and their immediate progenitors. We have established a relatively simple and inexpensive differentiation protocol that allows efficient generation of the pancreatic like, insulin-expressing cells from murine ESCs. Thus, this ESC to pancreatic lineage differentiation assay will be valuable to serve as a cellular tool for screening large number of molecules that could be used to treat diabetes.
 
 
 

H. Teresa Ku, Ph.D. Lab Members

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
H. Teresa Ku, Ph.D.
Professor
626-256-HOPE (4673), ext. 61174
 
Jeanne LeBon, Ph.D.
Assistant Research Professor
626-256-HOPE (4673), ext. 63796
 
Dan Gao, Ph.D.
Postdoctoral Fellow
626-256-HOPE (4673), ext. 62251
 
Liang Jin, Ph.D.
Postdoctoral Fellow
626-256-HOPE (4673), ext. 61449
 
Lena Wedeken, Ph.D.,
Postdoctoral Fellow and a CIRM Postdoctoral Scholar
626-256-HOPE (4673), ext. 33242
 
Stephanie Walker, B.S.
Research Associate I
626-256-HOPE (4673), ext. 31235
 
Nadiah Ghazalli, M.S.
Graduate Student and a CIRM Predoctoral Scholar
626-256-HOPE (4673), ext. 31235
 

Ku, Hsun Teresa, Ph.D. Research

Hsun Teresa Ku, Ph.D. Research

Identification and Characterization of Pancreatic Stem Cells
A functional pancreas consists of two types of tissue: exocrine and endocrine. The exocrine tissue mainly consists of acinar cells, which secrete bicarbonate and digestive enzymes. These secretions are collected by the pancreatic ductal system, which begins with centroacinar cells that are directly in contact with acinar cells. The prolongation of the terminal ducts, or alveoli, are lined by centroacinar cells and gradually merge into a main duct that drains into the duodenum. The endocrine tissue is organized as islets and contains cells that secrete glucagon, insulin, somatostatin, pancreatic polypeptide or grehlin. These endocrine hormones are released directly into the blood stream in response to metabolic signals.
 
Recently, there has been an intense interest in identifying pancreatic stem or progenitor cells, especially the endocrine progenitor cells, for the purpose of replacement therapy of Type 1 diabetes (T1D), a disease in which the insulin-secreting beta cells are specifically destroyed by autoimmunity. However, the existence of self-renewing multipotential stem cells in the pancreas remains elusive. Our laboratory is interested in the identification and characterization of pancreatic stem/progenitor cells, using both mouse models and cadaverous human pancreatic tissues for studies. We have established a quantitative and clonogenic progenitor cell assay in our laboratory, which will be a powerful tool to study the cellular and molecular mechanisms that govern the differentiation and proliferation of the pancreatic stem/progenitor cells at the single cell level.
 
Embryonic Stem Cell Therapy for Type 1 Diabetes
T1D is marked by a deficiency of the insulin-secreting β cells residing in the Islets of Langerhans within the pancreas due to autoimmune destruction. One of the long-term goals of our laboratory is to advance clinical cell-replacement therapy for patients with sever forms of T1D by developing a safe, reliable and abundant source of cells, derived from human stem cells that function like pancreatic islets. Toward this end, we have established an efficient and potentially cost-effective differentiation protocol, originally adapted from a mouse embryonic stem cell (ESC) differentiation method previously established in our laboratory, and generated a population of glucose-responsive, insulin-producing and secreting cells derived from human ESCs while in vitro. This cell population will be a suitable development candidate for clinical cell replacement therapy for T1D at City of Hope in the future.
 
Embryonic Stem Cells as a Cellular Tool for Screening of Molecules for Treatment of Diabetes
In the small molecule drug discovery field, the “bottom-up” approach, which is based on structural considerations of known targets, has not been as fruitful as was once promised. ESC technology ffers a potential solution to this bottleneck. ESCs can be grown in large numbers and maintained in a pluripotent state in vitro. They can also be induced in culture to differentiate into cells from all three germ layers in a relatively normal fashion that is faithful to development in vivo. Three properties make ES cells an ideal platform for drug discovery: first, ES cells can provide virtually inexhaustible quantities of target cells, which is necessary for screening of large numbers of compounds; second, ES cells can differentiate into mature cells with phenotypes that mimic their counterparts in vivo; and third, compared with immortalized cell lines, ES cells and their derivatives will provide a much more accurate platform for the “top-down” drug screening approach. Our laboratory is interested in high throughput screening (HTS) of small molecules that may affect proliferation, differentiation and/or maturation of the pancreatic insulin-producing  β cells and their immediate progenitors. We have established a relatively simple and inexpensive differentiation protocol that allows efficient generation of the pancreatic like, insulin-expressing cells from murine ESCs. Thus, this ESC to pancreatic lineage differentiation assay will be valuable to serve as a cellular tool for screening large number of molecules that could be used to treat diabetes.
 
 
 

Lab Members

H. Teresa Ku, Ph.D. Lab Members

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
H. Teresa Ku, Ph.D.
Professor
626-256-HOPE (4673), ext. 61174
 
Jeanne LeBon, Ph.D.
Assistant Research Professor
626-256-HOPE (4673), ext. 63796
 
Dan Gao, Ph.D.
Postdoctoral Fellow
626-256-HOPE (4673), ext. 62251
 
Liang Jin, Ph.D.
Postdoctoral Fellow
626-256-HOPE (4673), ext. 61449
 
Lena Wedeken, Ph.D.,
Postdoctoral Fellow and a CIRM Postdoctoral Scholar
626-256-HOPE (4673), ext. 33242
 
Stephanie Walker, B.S.
Research Associate I
626-256-HOPE (4673), ext. 31235
 
Nadiah Ghazalli, M.S.
Graduate Student and a CIRM Predoctoral Scholar
626-256-HOPE (4673), ext. 31235
 
Center for Biomedicine & Genetics
Our Center for Biomedicine & Genetics (CBG) manufactures promising new genetic and cellular agents created by researches for use inclinical trials. We are uniquely equipped to evaluate therapies swiftly and move lifesaving drugs into the marketplace with great speed.
City of Hope has been the home of many illustrious scientists, including six members of the prestigious National Academy of Sciences: Ernest Beutler, Alfred Knudson, Rachmiel Levine, Susumo Ohno, Eugene Roberts, and Arthur Riggs. Learn more about our current scientists and researchers.
Cytogenetics Office Location
City of Hope and Beckman Research Institute 1500 East Duarte Road Duarte, CA 91010-3000 Northwest Building
Room 2265

Phone: 626-256-HOPE (4673), ext. 62025
Fax: 626-301-8877

Biostatistics Office Location
City of Hope and Beckman Research Institute
1500 East Duarte Road
Duarte, CA  91010-3000

Information Sciences Building (#171)

Phone:  626-256-HOPE (4673), Ext. 61444
Fax:  626-471-7106
or 626-301-8802
 
Develop new therapies, diagnostics and preventions in the fight against cancer and other life-threatening diseases.
 
Support Our Research
By giving to City of Hope, you support breakthrough discoveries in laboratory research that translate into lifesaving treatments for patients with cancer and other serious diseases.
 
 
 
 
NEWS & UPDATES
  • Ryan Chavira was a senior in high school when she began feeling sluggish, fatigued and, well, “down.” Trips to the doctor ended in “you’re fine” pronouncements; blood tests results showed nothing of real concern. But Chavira’s grandmother had passed away from ovarian cancer when she was in eig...
  • Brain tumors are exceptionally difficult to treat. They can be removed surgically, but individual cancer cells may have already spread elsewhere in the brain and can escape the effects of both radiation and chemotherapy. To prevent tumors from recurring, doctors need a way to find and stop those invasive cancer...
  • Breast cancer risk is personal; breast cancer risk assessment should be, too. To that end, City of Hope researchers have developed a starting point to help women (and their doctors) with a family history of the disease begin that risk assessment process. The result is an iPhone app, called BRISK, for Breast Can...
  • When it comes to breast cancer, women aren’t limited to getting screened and, if diagnosed, making appropriate treatment choices. They can also take a proactive stance in the fight against breast cancer by understanding key risk factors and practicing lifestyle habits that can help reduce their own breast...
  • Cancers of the blood and immune system are considered to be among the most difficult-to-treat cancers. A world leader in the treatment of blood cancers, City of Hope is now launching an institute specifically focused on treating people with lymphoma, leukemia and myeloma, as well as other serious blood and bone...
  • Genetics, genes, genome, genetic risk … Such terms are becoming increasingly familiar to even nonresearchers as studies and information about the human make-up become more extensive and more critical. At City of Hope, these words have long been part of our vocabulary. Researchers and physicians are studyi...
  • Mammograms are currently the best method to detect breast cancer early, when it’s easier to treat and before it’s big enough to feel or cause symptoms. But recent mammogram screening guidelines may have left some women confused about when to undergo annual testing. Here Lusi Tumyan, M.D., chief of t...
  • Although chemotherapy can be effective in treating cancer, it can also exact a heavy toll on a patient’s health. One impressive alternative researchers have found is in the form of a vaccine. A type of immunotherapy, one part of the vaccine primes the body to react strongly against a tumor; the second part dire...
  • The breast cancer statistic is attention-getting: One in eight women will be diagnosed with breast cancer during her lifetime. That doesn’t mean that, if you’re one of eight women at a dinner table, one of you is fated to have breast cancer (read more on that breast cancer statistic), but it does mean that the ...
  • Rob Darakjian was diagnosed with acute lymphoblastic leukemia at just 19 years old. He began chemotherapy and was in and out of the hospital for four months. After his fourth round of treatment, he received a bone marrow transplantation from an anonymous donor. Today, he’s cancer free. In his first post, ...
  • Advanced age tops the list among breast cancer risk factor for women. Not far behind is family history and genetics. Two City of Hope researchers delving deep into these issues recently received important grants to advance their studies. Arti Hurria, M.D., director of the Cancer and Aging Research Program, and ...
  • City of Hope is extending the reach of its lifesaving mission well beyond U.S. borders. To that end, three distinguished City of Hope leaders visited China earlier this year to lay the foundation for the institution’s new International Medicine Program. The program is part of City of Hope’s strategi...
  • A hallmark of cancer is that it doesn’t always limit itself to a primary location. It spreads. Breast cancer and lung cancer in particular are prone to spread, or metastasize, to the brain. Often the brain metastasis isn’t discovered until years after the initial diagnosis, just when patients were beginning to ...
  • Blueberries, cinnamon, baikal scullcap, grape seed extract (and grape skin extract), mushrooms, barberry, pomegranates … all contain compounds with the potential to treat, or prevent, cancer. Scientists at City of Hope have found tantalizing evidence of this potential and are determined to explore it to t...
  • Most women who are treated for breast cancer with a mastectomy do not choose to undergo reconstructive surgery. The reasons for this, according to a recent JAMA Surgery study, vary. Nearly half say they do not want any additional surgery, while nearly 34 percent say breast cancer reconstruction simply isn’t imp...